Traders should monitor the post-interview period for any unexpected commentary or data points, but no immediate action is warranted based on this filing alone. The event may provide qualitative insights into trial progress or strategic direction.
Price Chart
Executive Summary
Cardiol Therapeutics announced a live interview featuring its CEO discussing the ongoing Phase III MAVERIC trial for recurrent pericarditis, recently published Phase II ARCHER trial results in acute myocarditis, and development of its next-generation drug CRD-38 for heart failure. This is promotional disclosure of upcoming commentary, not new clinical data.
Key Facts
- CEO David Elsley to participate in a live interview on X (formerly Twitter) with Barchart on April 14, 2026 at 12:00 PM EDT
- Interview will highlight the ongoing pivotal Phase III MAVERID trial of CardiolRx in recurrent pericarditis
- Discussion includes recently published results from the Phase II ARCHER trial of CardiolRx in acute myocarditis
- Company will also discuss CRD-38, a subcutaneous formulation in development for heart failure
- No new clinical data or material updates were released in the filing
Financial Impact
No immediate financial impact — this is a promotional event announcement, not a material operational update
Risk Factors
- Forward-looking statements are subject to risks and uncertainties, including those outlined in the company's Annual Information Form
- Clinical trial outcomes remain uncertain and could differ from management's expectations
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001062993-26-001963 |
| Document: form6k.htm | 0001062993-26-001963 |
| Document: 0001062993-26-001963-index-headers.html | 0001062993-26-001963 |
| Document: 0001062993-26-001963-index.html | 0001062993-26-001963 |
| Document: 0001062993-26-001963.txt | 0001062993-26-001963 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 23, 2026 4w ago | SC 13G/A | $1.77 | awaiting T+60 | — | $1.15 (−34.75%) |
Sep 23, 2026 4w ago | 6-K | $1.77 | awaiting T+60 | — | $1.15 (−34.75%) |
Sep 16, 2026 5w ago | 6-K | $1.90 | awaiting T+60 | — | $1.15 (−39.21%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.15 (−42.11%) |
Sep 10, 2026 6w ago | 6-K | $2.00 | awaiting T+60 | — | $1.15 (−42.11%) |
Sep 9, 2026 6w ago | 6-K | $2.29 | awaiting T+60 | — | $1.15 (−49.45%) |
Aug 5, 2026 11w ago | 6-K | $1.34 | awaiting T+60 | — | $1.15 (−13.81%) |
Jul 14, 2026 15w ago | 6-K | $1.15 $1.32 | ▲ +14.78% | ▲ +11.41% | $1.15 (+0.43%) |
Jul 9, 2026 15w ago | 6-K | $0.9920 $1.41 | ▲ +42.14% | ▲ +40.50% | $1.15 (+16.43%) |
May 26, 2026 22w ago | 6-K | $1.30 $1.96 | ▲ +50.77% | ▲ +48.04% | $1.15 (−11.15%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers